Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This Investigation is to be performed for the purpose of assessing the following information
in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX
2 mg Capsule for the treatment of Rheumatoid Arthritis (RA) at the dose higher than 8
mg/week.
1. Condition of occurrence of ADRs
2. Factors considered to affect safety
3. Verification of efficacy